Moderna creator Flagship Pioneering brings £100M AI lab to London

U.S. biotech venture creator Flagship Pioneering is investing an initial £100 million (€120 million) to establish an AI-focused company-creation lab in London, marking the first expansion of its company-building model outside the United States.

ADVERTISEMENT

Why it matters: Rather than investing in existing startups, Flagship plans to create entirely new companies in the U.K., combining its experience in biotechnology with artificial intelligence. The move brings one of the U.S. biotech industry’s most established company creators directly into the European innovation ecosystem.

The new Flagship Origination Lab will operate as part of Flagship Labs, the group’s company-creation arm based in Cambridge, Massachusetts. It will focus on developing AI-native platforms across human health, sustainability and other scientific fields. Flagship expects to recruit and train an initial team of about 50 scientist-entrepreneurs and operators in the U.K.

By the numbers: Flagship has committed an initial £100 million to establish the London operation, with ambitions to attract another £500 million (€600 million) through partnerships.

The initial funding will cover the establishment of the Lab, recruitment, development of scientific capabilities and investments in the first companies, a spokesperson from Flagship told European Biotechnology. The firm did not disclose how much of the commitment will go toward operating the Lab versus directly financing new ventures.

As for the additional £500 million, the money has not yet been secured. “We are in discussions with a number of potential partners and have received strong interest,” Flagship said.

Flagship founder and CEO Noubar Afeyan described the investment as a long-term commitment to the U.K. “By bringing Flagship’s approach to company origination and scaling to the U.K., we will complement and amplify the country’s existing strengths,” he said.

Why London: Flagship has been building relationships in the U.K. since opening a London office and signing a memorandum of understanding with the British government in 2023. The firm subsequently established Quotient Therapeutics as its first transatlantic company and expanded its U.K. clinical research activities through portfolio companies including Generate:Biomedicines.

“The U.K. brings together world-class science, deep talent, and a culture of ambition,” Flagship told European Biotechnology. Beyond the talent pool, the firm highlighted the country’s clinical trial infrastructure, genomic and health data resources, scientific capabilities and regulatory environment. “The U.K. was the clear choice to begin replicating our origination capabilities,” the company said, adding that “it is the first location, and we may consider others over time.”

Backstory: Flagship has played a considerable role in shaping the U.S. biotech industry over the past quarter-century. Founded in 2000 by Noubar Afeyan, Flagship operates differently from conventional venture capital firms. Instead of identifying promising startups and buying stakes in them, its scientists and entrepreneurs develop scientific concepts, test their commercial potential and establish companies to pursue them. Its best-known creation is Moderna, founded in 2010, which went on to become one of the world’s most prominent mRNA vaccine developers.

Flagship says it has created more than 130 companies since its founding, with more than 40 businesses in its current ecosystem. Beyond Moderna, its portfolio includes Tessera Therapeutics, which is developing gene-writing technologies; Repertoire Immune Medicines, focused on immune-targeted therapies; and Generate:Biomedicines, which uses AI to design protein therapeutics.

The group reported $14 billion in assets under its direction following its latest capital raise in 2024.

Flagship intends to replicate that company-building process in London, rather than use the Lab to invest in startups that already exist. “Flagship is not a traditional investor in existing startups; its primary purpose is to conceive, create, and grow our own companies,” the firm explained. Although it expects to collaborate with British universities and research institutions, scientific concepts will primarily be originated through Flagship’s own process.

Track record in AI: Flagship’s emphasis on AI-native companies builds on several ventures it has already established in the field. “AI is increasingly foundational to how Flagship creates and builds companies, embedded in our approach to asking scientific questions, generating hypotheses, designing experiments, and developing products,” the company told European Biotechnology.

Generate:Biomedicines is arguably its most advanced example. Founded in 2018, the now Nasdaq-listed biotech uses machine learning and experimental data to design therapeutic proteins. Its lead antibody, GB-0895, is in two Phase 3 studies for severe asthma, while other candidates are in earlier clinical development. Generate has also secured research partnerships with Amgen, Novartis and, most recently, Denmark’s Zealand Pharma.

Lila Sciences, another Flagship company, takes a different approach, combining AI models, robotics and automated experiments in what it calls AI Science Factories. Founded in 2023, Lila has raised $550 million to develop its platform across biology, chemistry and materials science. The company has reported preclinical work in RNA therapeutics and AI-directed materials discovery, although its technology has yet to establish a clinical track record comparable to Generate’s.

What’s next: Flagship has not disclosed any initial projects or founding teams for its London Lab. “We are focused first on building the right foundation: assembling the team, establishing the Lab’s capabilities, and advancing the most promising scientific opportunities,” the company said.

Nor has it committed to a timeline for launching its first ventures. “Company creation does not follow a fixed timetable; it follows the science,” Flagship explained. “We expect to begin originating and testing ideas from the outset, and we will share more as those efforts mature into companies.”

Bottom line: The investment gives the U.K. a direct connection to one of biotech’s most established venture creators. The next test will be whether Flagship can reproduce its U.S. company-building model in Europe and turn the ambition behind its AI-native strategy into new businesses.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!